Abiraterone
The serum concentration of Triamterene can be increased when it is combined with Abiraterone.
Acebutolol
The risk or severity of adverse effects can be increased when Triamterene is combined with Acebutolol.
Aceclofenac
Aceclofenac may decrease the antihypertensive activities of Triamterene.
Advertisement
Acemetacin
The risk or severity of renal failure can be increased when Triamterene is combined with Acemetacin.
Acetyl salicylate
Acetylsalicylic acid may decrease the antihypertensive activities of Triamterene.
Acetyldigitoxin
The therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Triamterene.
Advertisement
Adapalene
Adapalene may decrease the antihypertensive activities of Triamterene.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Triamterene.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Triamterene.
Advertisement
Aliskiren
The risk or severity of adverse effects can be increased when Triamterene is combined with Aliskiren.
Alminoprofen
Alminoprofen may decrease the antihypertensive activities of Triamterene.
Alphaprodine
The risk or severity of adverse effects can be increased when Alphaprodine is combined with Triamterene.
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Triamterene.
Amifostine Anhydrous
The risk or severity of adverse effects can be increased when Amifostine is combined with Triamterene.
Amiloride
The risk or severity of adverse effects can be increased when Triamterene is combined with Amiloride.
Amiodarone
The risk or severity of adverse effects can be increased when Amiodarone is combined with Triamterene.
Amlodipine
The risk or severity of adverse effects can be increased when Amlodipine is combined with Triamterene.
Ammonium Chloride
The risk or severity of adverse effects can be increased when Triamterene is combined with Ammonium chloride.
Amobarbital
Amobarbital may increase the hypotensive activities of Triamterene.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Triamterene.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Triamterene.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Triamterene is combined with Amyl Nitrite.
Anhydrous Tacrolimus
The risk or severity of hyperkalemia can be increased when Triamterene is combined with Tacrolimus.
Antipyrine
Antipyrine may decrease the antihypertensive activities of Triamterene.
Apazone
Azapropazone may decrease the antihypertensive activities of Triamterene.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Triamterene.
Apraclonidine
The risk or severity of adverse effects can be increased when Triamterene is combined with Apraclonidine.
Apremilast
Apremilast may decrease the antihypertensive activities of Triamterene.
Ardeparin
Ardeparin may increase the hyperkalemic activities of Triamterene.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Triamterene.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Triamterene.
Aspirin
Acetylsalicylic acid may decrease the antihypertensive activities of Triamterene.
Atenolol
The risk or severity of adverse effects can be increased when Atenolol is combined with Triamterene.
Azelastine
Azelastine may decrease the antihypertensive activities of Triamterene.
Azilsartan
Azilsartan medoxomil may increase the hyperkalemic activities of Triamterene.
Azilsartan kamedoxomil
Azilsartan medoxomil may increase the hyperkalemic activities of Triamterene.
Azilsartan Medoxomil
Azilsartan medoxomil may increase the hyperkalemic activities of Triamterene.
Azithromycin
The metabolism of Triamterene can be decreased when combined with Azithromycin.
Balsalazide
Balsalazide may decrease the antihypertensive activities of Triamterene.
Barbexaclone
Barbexaclone may increase the hypotensive activities of Triamterene.
Barbital
Barbital may increase the hypotensive activities of Triamterene.
Bemiparin
Bemiparin may increase the hyperkalemic activities of Triamterene.
Benazepril
Triamterene may increase the hyperkalemic activities of Benazepril.
Bendroflumethiazide
The risk or severity of adverse effects can be increased when Triamterene is combined with Bendroflumethiazide.
Benzydamine
Benzydamine may decrease the antihypertensive activities of Triamterene.
Bepridil
The risk or severity of adverse effects can be increased when Bepridil is combined with Triamterene.
Betaxolol
The risk or severity of adverse effects can be increased when Betaxolol is combined with Triamterene.
Bisoprolol
The risk or severity of adverse effects can be increased when Triamterene is combined with Bisoprolol.
Bortezomib
The metabolism of Triamterene can be decreased when combined with Bortezomib.
Bretylium
The risk or severity of adverse effects can be increased when Triamterene is combined with Bretylium.
Brimonidine
The risk or severity of adverse effects can be increased when Triamterene is combined with Brimonidine.
Bromfenac
Bromfenac may decrease the antihypertensive activities of Triamterene.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Triamterene.
Bufexamac
Bufexamac may decrease the antihypertensive activities of Triamterene.
Bumetanide
The risk or severity of adverse effects can be increased when Triamterene is combined with Bumetanide.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Triamterene.
Buprenorphine
The risk or severity of adverse effects can be increased when Buprenorphine is combined with Triamterene.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Triamterene.
Caffeine
The metabolism of Triamterene can be decreased when combined with Caffeine.
Canagliflozin
Canagliflozin may increase the hyperkalemic activities of Triamterene.
Canagliflozin Anhydrous
Canagliflozin may increase the hyperkalemic activities of Triamterene.
Candesartan
Candesartan may increase the hyperkalemic activities of Triamterene.
Candesartan Cilexetil
The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Triamterene.
Captopril
Triamterene may increase the hyperkalemic activities of Captopril.
Carprofen
Carprofen may decrease the antihypertensive activities of Triamterene.
Carteolol
The risk or severity of adverse effects can be increased when Triamterene is combined with Carteolol.
Carvedilol
The risk or severity of adverse effects can be increased when Triamterene is combined with Carvedilol.
Celecoxib
Celecoxib may decrease the antihypertensive activities of Triamterene.
Certoparin
Certoparin may increase the hyperkalemic activities of Triamterene.
Chloroquine
Chloroquine may decrease the antihypertensive activities of Triamterene.
Chlorothiazide
The risk or severity of adverse effects can be increased when Triamterene is combined with Chlorothiazide.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triamterene.
Chlorthalidone
The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Triamterene.
Choline Magnesium Trisalicyclate
Choline magnesium trisalicylate may decrease the antihypertensive activities of Triamterene.
Cilazapril
Triamterene may increase the hyperkalemic activities of Cilazapril.
Citalopram
The metabolism of Triamterene can be decreased when combined with Citalopram.
Clevidipine
The risk or severity of adverse effects can be increased when Triamterene is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Triamterene is combined with Clevidipine.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Triamterene.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Triamterene.
Clonidine
The risk or severity of adverse effects can be increased when Triamterene is combined with Clonidine.
Clonixin
Clonixin may decrease the antihypertensive activities of Triamterene.
Clotrimazole
The metabolism of Triamterene can be decreased when combined with Clotrimazole.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Triamterene.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Triamterene.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Triamterene.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Triamterene.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Triamterene.
Curcumin
Curcumin may decrease the antihypertensive activities of Triamterene.
Cyclosporine
The risk or severity of hyperkalemia can be increased when Triamterene is combined with Cyclosporine.
Cyproterone Acetate
The serum concentration of Triamterene can be decreased when it is combined with Cyproterone acetate.
Dalteparin
Dalteparin may increase the hyperkalemic activities of Triamterene.
Dapagliflozin
The risk or severity of adverse effects can be increased when Triamterene is combined with Dapagliflozin.
Deferasirox
The serum concentration of Triamterene can be increased when it is combined with Deferasirox.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Triamterene.
Deslanoside
The therapeutic efficacy of Deslanoside can be decreased when used in combination with Triamterene.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Triamterene is combined with Dexmedetomidine.
Dextromoramide
The risk or severity of adverse effects can be increased when Dextromoramide is combined with Triamterene.
Dezocine
The risk or severity of adverse effects can be increased when Dezocine is combined with Triamterene.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Triamterene is combined with Diclofenamide.
Diclofenac
Diclofenac may decrease the antihypertensive activities of Triamterene.
Diflunisal
Diflunisal may decrease the antihypertensive activities of Triamterene.
Digitoxin
The therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene.
Digoxin
The therapeutic efficacy of Digoxin can be decreased when used in combination with Triamterene.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triamterene.
Diltiazem
The risk or severity of adverse effects can be increased when Diltiazem is combined with Triamterene.
Dinutuximab
The risk or severity of adverse effects can be increased when Triamterene is combined with Dinutuximab.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triamterene.
Dipyridamole
The risk or severity of adverse effects can be increased when Triamterene is combined with Dipyridamole.
Dipyrone
Metamizole may decrease the antihypertensive activities of Triamterene.
Dofetilide
The serum concentration of Dofetilide can be increased when it is combined with Triamterene.
Dothiepin
The metabolism of Triamterene can be decreased when combined with Dosulepin.
Doxazosin
The risk or severity of adverse effects can be increased when Triamterene is combined with Doxazosin.
Drospirenone
Drospirenone may increase the hyperkalemic activities of Triamterene.
Droxicam
Droxicam may decrease the antihypertensive activities of Triamterene.
Duloxetine
Triamterene may increase the orthostatic hypotensive activities of Duloxetine.
Empagliflozin
The risk or severity of adverse effects can be increased when Triamterene is combined with Empagliflozin.
Enalapril
Triamterene may increase the hyperkalemic activities of Enalapril.
Enalaprilat
Triamterene may increase the hyperkalemic activities of Enalaprilat.
Enalaprilat Anhydrous
Triamterene may increase the hyperkalemic activities of Enalaprilat.
Enoxaparin
Enoxaparin may increase the hyperkalemic activities of Triamterene.
Enoxaparin sodium
Enoxaparin may increase the hyperkalemic activities of Triamterene.
Eplerenone
Eplerenone may increase the hyperkalemic activities of Triamterene.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Triamterene.
Eprosartan
Eprosartan may increase the hyperkalemic activities of Triamterene.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Triamterene.
Etanercept
Etanercept may decrease the antihypertensive activities of Triamterene.
Ethacrynate
The risk or severity of adverse effects can be increased when Triamterene is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Triamterene is combined with Etacrynic acid.
Ethylmorphine
The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triamterene.
Etodolac
Etodolac may decrease the antihypertensive activities of Triamterene.
Etofenamate
Etofenamate may decrease the antihypertensive activities of Triamterene.
Etoricoxib
Etoricoxib may decrease the antihypertensive activities of Triamterene.
Evening primrose oil
Evening primrose oil may decrease the antihypertensive activities of Triamterene.
Felbinac
Felbinac may decrease the antihypertensive activities of Triamterene.
Felodipine
The risk or severity of adverse effects can be increased when Triamterene is combined with Felodipine.
Fenbufen
Fenbufen may decrease the antihypertensive activities of Triamterene.
Fenoldopam
The risk or severity of adverse effects can be increased when Fenoldopam is combined with Triamterene.
Fenoprofen
Fenoprofen may decrease the antihypertensive activities of Triamterene.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Triamterene.
Ferulic Acid
Ferulic acid may decrease the antihypertensive activities of Triamterene.
Floctafenine
Floctafenine may decrease the antihypertensive activities of Triamterene.
Flurbiprofen
Flurbiprofen may decrease the antihypertensive activities of Triamterene.
Fluvoxamine
The metabolism of Triamterene can be decreased when combined with Fluvoxamine.
Fosinopril
Triamterene may increase the hyperkalemic activities of Fosinopril.
Furosemide
The risk or severity of adverse effects can be increased when Triamterene is combined with Furosemide.
Guanfacine
The risk or severity of adverse effects can be increased when Triamterene is combined with Guanfacine.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Triamterene.
Heparin
Heparin may increase the hyperkalemic activities of Triamterene.
Heroin
The risk or severity of adverse effects can be increased when Heroin is combined with Triamterene.
Hexobarbital
Hexobarbital may increase the hypotensive activities of Triamterene.
Hydralazine
The risk or severity of adverse effects can be increased when Triamterene is combined with Hydralazine.
Hydrochlorothiazide
The risk or severity of adverse effects can be increased when Triamterene is combined with Hydrochlorothiazide.
Hydrocodone
The risk or severity of adverse effects can be increased when Hydrocodone is combined with Triamterene.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Hydrocodone is combined with Triamterene.
Hydroflumethiazide
The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Triamterene.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triamterene.
Ibuprofen
Ibuprofen may decrease the antihypertensive activities of Triamterene.
Icatibant
Icatibant may decrease the antihypertensive activities of Triamterene.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Triamterene.
Imidapril
Triamterene may increase the hyperkalemic activities of Imidapril.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Triamterene.
Indapamide
The risk or severity of adverse effects can be increased when Triamterene is combined with Indapamide.
Indobufen
Indobufen may decrease the antihypertensive activities of Triamterene.
Indomethacin
Indomethacin may increase the nephrotoxic activities of Triamterene.
Indoramin
The risk or severity of adverse effects can be increased when Indoramin is combined with Triamterene.
Irbesartan
Irbesartan may increase the hyperkalemic activities of Triamterene.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Triamterene.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Triamterene.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Triamterene is combined with Isoxsuprine.
Isradipine
The risk or severity of adverse effects can be increased when Isradipine is combined with Triamterene.
Kebuzone
Kebuzone may decrease the antihypertensive activities of Triamterene.
Ketoprofen
Ketoprofen may decrease the antihypertensive activities of Triamterene.
Ketorolac
Ketorolac may decrease the antihypertensive activities of Triamterene.
Labetalol
The risk or severity of adverse effects can be increased when Triamterene is combined with Labetalol.
Lacidipine
Triamterene may increase the hypotensive activities of Lacidipine.
Leflunomide
Leflunomide may decrease the antihypertensive activities of Triamterene.
Lercanidipine
The risk or severity of adverse effects can be increased when Lercanidipine is combined with Triamterene.
Levobunolol
The risk or severity of adverse effects can be increased when Triamterene is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Triamterene.
Levodopa
Triamterene may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl
The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triamterene.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Triamterene.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Triamterene.
Lidocaine
The metabolism of Triamterene can be decreased when combined with Lidocaine.
Limonene, (+)-
(4R)-limonene may decrease the antihypertensive activities of Triamterene.
Lisinopril
Triamterene may increase the hyperkalemic activities of Lisinopril.
Lisinopril Anhydrous
Triamterene may increase the hyperkalemic activities of Lisinopril.
Lofexidine
The risk or severity of adverse effects can be increased when Lofexidine is combined with Triamterene.
Lornoxicam
Lornoxicam may decrease the antihypertensive activities of Triamterene.
Losartan
Losartan may increase the hyperkalemic activities of Triamterene.
Loxoprofen
Loxoprofen may decrease the antihypertensive activities of Triamterene.
Magnesium Salicylate
Magnesium salicylate may decrease the antihypertensive activities of Triamterene.
Mannitol
The risk or severity of adverse effects can be increased when Triamterene is combined with Mannitol.
Masoprocol
Masoprocol may decrease the antihypertensive activities of Triamterene.
Mecamylamine
The risk or severity of adverse effects can be increased when Triamterene is combined with Mecamylamine.
Meclofenamate
Meclofenamic acid may decrease the antihypertensive activities of Triamterene.
Meclofenamic Acid
Meclofenamic acid may decrease the antihypertensive activities of Triamterene.
Mefenamic Acid
Mefenamic acid may decrease the antihypertensive activities of Triamterene.
Meloxicam
Meloxicam may decrease the antihypertensive activities of Triamterene.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Triamterene.
Mephobarbital
Methylphenobarbital may increase the hypotensive activities of Triamterene.
Mepirodipine
The risk or severity of adverse effects can be increased when Barnidipine is combined with Triamterene.
Mesalamine
Mesalazine may decrease the antihypertensive activities of Triamterene.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Triamterene.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Triamterene.
Methazolamide
The risk or severity of adverse effects can be increased when Triamterene is combined with Methazolamide.
Methohexital
Methohexital may increase the hypotensive activities of Triamterene.
Methyclothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Triamterene.
Methyldopa
The risk or severity of adverse effects can be increased when Triamterene is combined with Methyldopa.
METHYLDOPA ANHYDROUS
The risk or severity of adverse effects can be increased when Triamterene is combined with Methyldopa.
Metipranolol
The risk or severity of adverse effects can be increased when Triamterene is combined with Metipranolol.
Metolazone
The risk or severity of adverse effects can be increased when Triamterene is combined with Metolazone.
Metoprolol
The risk or severity of adverse effects can be increased when Metoprolol is combined with Triamterene.
Mexiletine
The metabolism of Triamterene can be decreased when combined with Mexiletine.
Midostaurin
The metabolism of Triamterene can be decreased when combined with Midostaurin.
Minoxidil
The risk or severity of adverse effects can be increased when Minoxidil is combined with Triamterene.
Moexipril
Triamterene may increase the hyperkalemic activities of Moexipril.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Triamterene.
Moxonidine
The risk or severity of adverse effects can be increased when Moxonidine is combined with Triamterene.
MYCOPHENOLATE
Mycophenolic acid may decrease the antihypertensive activities of Triamterene.
Mycophenolate Mofetil
Mycophenolate mofetil may decrease the antihypertensive activities of Triamterene.
Mycophenolic Acid
Mycophenolic acid may decrease the antihypertensive activities of Triamterene.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Triamterene.
Nabumetone
Nabumetone may decrease the antihypertensive activities of Triamterene.
Nadolol
The risk or severity of adverse effects can be increased when Triamterene is combined with Nadolol.
Nadroparin
Nadroparin may increase the hyperkalemic activities of Triamterene.
Naftifine
Naftifine may decrease the antihypertensive activities of Triamterene.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Triamterene.
Naproxen
Naproxen may decrease the antihypertensive activities of Triamterene.
Nebivolol
The risk or severity of adverse effects can be increased when Triamterene is combined with Nebivolol.
Nepafenac
Nepafenac may decrease the antihypertensive activities of Triamterene.
Nesiritide
The risk or severity of adverse effects can be increased when Triamterene is combined with Nesiritide.
Nevirapine
The metabolism of Triamterene can be decreased when combined with Nevirapine.
Nicardipine
The risk or severity of adverse effects can be increased when Triamterene is combined with Nicardipine.
Nicorandil
Nicorandil may increase the hyperkalemic activities of Triamterene.
Nifedipine
The risk or severity of adverse effects can be increased when Triamterene is combined with Nifedipine.
Niflumic Acid
Niflumic Acid may decrease the antihypertensive activities of Triamterene.
Nilvadipine
The risk or severity of adverse effects can be increased when Nilvadipine is combined with Triamterene.
Nimesulide
Nimesulide may decrease the antihypertensive activities of Triamterene.
Nimodipine
The risk or severity of adverse effects can be increased when Triamterene is combined with Nimodipine.
Nisoldipine
The risk or severity of adverse effects can be increased when Triamterene is combined with Nisoldipine.
Nitrendipine
The risk or severity of adverse effects can be increased when Nitrendipine is combined with Triamterene.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Triamterene.
Nitroglycerin
The risk or severity of adverse effects can be increased when Triamterene is combined with Nitroglycerin.
Nitroprusside
The risk or severity of adverse effects can be increased when Nitroprusside is combined with Triamterene.
Normethadone
The risk or severity of adverse effects can be increased when Normethadone is combined with Triamterene.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Triamterene.
Oenothera biennis seed extract
Evening primrose oil may decrease the antihypertensive activities of Triamterene.
Olmesartan
Olmesartan may increase the hyperkalemic activities of Triamterene.
Olopatadine
Olopatadine may decrease the antihypertensive activities of Triamterene.
Olsalazine
Olsalazine may decrease the antihypertensive activities of Triamterene.
Opium
The risk or severity of adverse effects can be increased when Opium is combined with Triamterene.
Osimertinib
The serum concentration of Triamterene can be decreased when it is combined with Osimertinib.
Ouabain
The therapeutic efficacy of Ouabain can be decreased when used in combination with Triamterene.
Ovine Digoxin Immune Fab
The therapeutic efficacy of Digoxin Immune Fab (Ovine) can be decreased when used in combination with Triamterene.
Oxaprozin
Oxaprozin may decrease the antihypertensive activities of Triamterene.
Oxprenolol
The risk or severity of adverse effects can be increased when Oxprenolol is combined with Triamterene.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Triamterene.
Oxymorphone
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Triamterene.
Oxyphenbutazone
Oxyphenbutazone may decrease the antihypertensive activities of Triamterene.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Triamterene.
Papaverine
The risk or severity of adverse effects can be increased when Triamterene is combined with Papaverine.
Parecoxib
Parecoxib may decrease the antihypertensive activities of Triamterene.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Triamterene.
Parnaparin
Parnaparin may increase the hyperkalemic activities of Triamterene.
Parthenolide
Parthenolide may decrease the antihypertensive activities of Triamterene.
Peginterferon Alfa-2b
The serum concentration of Triamterene can be increased when it is combined with Peginterferon alfa-2b.
Penbutolol
The risk or severity of adverse effects can be increased when Triamterene is combined with Penbutolol.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Triamterene.
Pentobarbital
Pentobarbital may increase the hypotensive activities of Triamterene.
Perindopril
Triamterene may increase the hyperkalemic activities of Perindopril.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Triamterene.
Phenobarbital
Phenobarbital may increase the hypotensive activities of Triamterene.
Phenoxybenzamine
The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Triamterene.
Phentolamine
The risk or severity of adverse effects can be increased when Phentolamine is combined with Triamterene.
Phentolamine Mesylate
The risk or severity of adverse effects can be increased when Phentolamine is combined with Triamterene.
Phenylbutazone
Phenylbutazone may decrease the antihypertensive activities of Triamterene.
Pimecrolimus
Pimecrolimus may decrease the antihypertensive activities of Triamterene.
Pindolol
The risk or severity of adverse effects can be increased when Triamterene is combined with Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Triamterene.
Pirfenidone
Pirfenidone may decrease the antihypertensive activities of Triamterene.
Pirinitramide
The risk or severity of adverse effects can be increased when Piritramide is combined with Triamterene.
Piroxicam
Piroxicam may decrease the antihypertensive activities of Triamterene.
Piroxicam-Beta-Cyclodextrin
Piroxicam may decrease the antihypertensive activities of Triamterene.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Triamterene.
Prazosin
The risk or severity of adverse effects can be increased when Triamterene is combined with Prazosin.
Primidone
Primidone may increase the hypotensive activities of Triamterene.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Triamterene.
Propoxyphene
The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triamterene.
Propranolol
The risk or severity of adverse effects can be increased when Triamterene is combined with Propranolol.
Proscillaridin
The therapeutic efficacy of Proscillaridin can be decreased when used in combination with Triamterene.
Quetiapine
The risk or severity of adverse effects can be increased when Triamterene is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Triamterene is combined with Quetiapine.
Quinapril
Triamterene may increase the hyperkalemic activities of Quinapril.
Quinidine
The therapeutic efficacy of Quinidine can be decreased when used in combination with Triamterene.
Ramipril
Triamterene may increase the hyperkalemic activities of Ramipril.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Triamterene.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Triamterene.
Rescinnamine
Triamterene may increase the hyperkalemic activities of Rescinnamine.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Triamterene.
Resveratrol
Resveratrol may decrease the antihypertensive activities of Triamterene.
Reviparin
Reviparin may increase the hyperkalemic activities of Triamterene.
Reviparin sodium
Reviparin may increase the hyperkalemic activities of Triamterene.
Riociguat
The risk or severity of adverse effects can be increased when Triamterene is combined with Riociguat.
Risperidone
Triamterene may increase the hypotensive activities of Risperidone.
Rofecoxib
Rofecoxib may decrease the antihypertensive activities of Triamterene.
Ropinirole
The metabolism of Triamterene can be decreased when combined with Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Triamterene.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Triamterene.
Rucaparib
The metabolism of Triamterene can be decreased when combined with Rucaparib.
Sacubitril
Sacubitril may increase the hyperkalemic activities of Triamterene.
Salicylamide
Salicylamide may decrease the antihypertensive activities of Triamterene.
Salicylic Acid
Salicylic acid may decrease the antihypertensive activities of Triamterene.
Salsalate
Salsalate may decrease the antihypertensive activities of Triamterene.
Saralasin
Saralasin may increase the hyperkalemic activities of Triamterene.
Secobarbital
Secobarbital may increase the hypotensive activities of Triamterene.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Triamterene.
Serratiopeptidase
Serrapeptase may decrease the antihypertensive activities of Triamterene.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Triamterene.
Simeprevir
The metabolism of Triamterene can be decreased when combined with Simeprevir.
Sodium Phosphate
Triamterene may increase the nephrotoxic activities of Sodium phosphate.
Sodium Phosphate, Monobasic
Triamterene may increase the nephrotoxic activities of Sodium phosphate.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Triamterene may increase the nephrotoxic activities of Sodium phosphate.
Sotalol
The risk or severity of adverse effects can be increased when Triamterene is combined with Sotalol.
Spirapril
Triamterene may increase the hyperkalemic activities of Spirapril.
Spironolactone
Triamterene may increase the hyperkalemic activities of Spironolactone.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Triamterene.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Triamterene.
Sulfasalazine
Sulfasalazine may decrease the antihypertensive activities of Triamterene.
Sulindac
Sulindac may decrease the antihypertensive activities of Triamterene.
Suprofen
Suprofen may decrease the antihypertensive activities of Triamterene.
Tacrolimus
The risk or severity of hyperkalemia can be increased when Triamterene is combined with Tacrolimus.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Triamterene.
Tapentadol
The risk or severity of adverse effects can be increased when Tapentadol is combined with Triamterene.
Telmisartan
Telmisartan may increase the hyperkalemic activities of Triamterene.
Tenofovir Disoproxil
The metabolism of Triamterene can be decreased when combined with Tenofovir disoproxil.
Tenoxicam
Tenoxicam may decrease the antihypertensive activities of Triamterene.
Terazosin
The risk or severity of adverse effects can be increased when Triamterene is combined with Terazosin.
Teriflunomide
The serum concentration of Triamterene can be decreased when it is combined with Teriflunomide.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Triamterene.
Theophylline
The metabolism of Triamterene can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Triamterene can be decreased when combined with Theophylline.
Thiamylal
Thiamylal may increase the hypotensive activities of Triamterene.
Thiopental
Thiopental may increase the hypotensive activities of Triamterene.
Thiopental Sodium
Thiopental may increase the hypotensive activities of Triamterene.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Triamterene.
Tiaprofenic Acid
Tiaprofenic acid may decrease the antihypertensive activities of Triamterene.
Ticlopidine
The metabolism of Triamterene can be decreased when combined with Ticlopidine.
Timolol
The risk or severity of adverse effects can be increased when Timolol is combined with Triamterene.
Timolol Anhydrous
The risk or severity of adverse effects can be increased when Timolol is combined with Triamterene.
Tinzaparin
Tinzaparin may increase the hyperkalemic activities of Triamterene.
Tinzaparin sodium
Tinzaparin may increase the hyperkalemic activities of Triamterene.
Tizanidine
The risk or severity of adverse effects can be increased when Triamterene is combined with Tizanidine.
Tolazoline
The risk or severity of adverse effects can be increased when Tolazoline is combined with Triamterene.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Triamterene.
Tolfenamic Acid
Tolfenamic Acid may decrease the antihypertensive activities of Triamterene.
Tolmetin
Tolmetin may decrease the antihypertensive activities of Triamterene.
Tolvaptan
Tolvaptan may increase the hyperkalemic activities of Triamterene.
Torsemide
The risk or severity of adverse effects can be increased when Torasemide is combined with Triamterene.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Triamterene.
Trandolapril
Triamterene may increase the hyperkalemic activities of Trandolapril.
Tranilast
Tranilast may decrease the antihypertensive activities of Triamterene.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triamterene.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Triamterene.
Valdecoxib
Valdecoxib may decrease the antihypertensive activities of Triamterene.
Valsartan
Valsartan may increase the hyperkalemic activities of Triamterene.
Vemurafenib
The serum concentration of Triamterene can be increased when it is combined with Vemurafenib.
Verapamil
The risk or severity of adverse effects can be increased when Triamterene is combined with Verapamil.
Zileuton
Zileuton may decrease the antihypertensive activities of Triamterene.
Zofenopril
Triamterene may increase the hyperkalemic activities of Zofenopril.
Zomepirac
Zomepirac may decrease the antihypertensive activities of Triamterene.
